Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of the Safety and Efficacy of CORT125134 in the Treatment of Endogenous Cushing's Syndrome

NCT02804750 is registered in ClinicalTrials.gov with Corcept Therapeutics as lead sponsor.

NCT NCT02804750
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02804750 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of the Safety and Efficacy of CORT125134 in the Treatment of Endogenous Cushing's Syndrome
Lead sponsor
Corcept Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2016
Completion date
September 30, 2018
Enrollment
35 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

cushing's syndrome